$16.77 B
Share price
Change (1 day)
Change (1 year)
Eisai is a Japanese pharmaceutical company that is engaged in the R&D of drugs for the treatment of dementia and Alzheimer.

Revenue for Eisai (4523.T)

Revenue in 2023 (TTM): $5.48 B

According to Eisai's latest financial reports the company's current revenue (TTM) is $5.48 B. In 2022 the company made a revenue of $5.55 B a decrease over the years 2021 revenue that were of $6.36 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Eisai from 2009 to 2023

Annual revenue

Year Revenue Change
2023 (TTM)$5.48 B-1.18%
2022$5.55 B-12.69%
2021$6.36 B-4.62%
2020$6.67 B9.99%
2019$6.06 B6.52%
2018$5.69 B12.19%
2017$5.07 B3.14%
2016$4.92 B4.87%
2015$4.69 B-9.82%
2014$5.20 B-12.56%
2013$5.94 B-15.59%
2012$7.04 B-15.34%
2011$8.32 B-11.35%
2010$9.39 B12.42%
2009$8.35 B